earnings joining for for Good thank afternoon, and you Owlet's call. QX, us XXXX
a profitability. Before position and sustainable long-term to in focus the from a is on March. cost and we objectives discipline our with details, on update goal clearance dive operational into our pathway Through products growth last let's our revisit FDA category management, Owlet defining to and
a by run has cost health these to QX deliver improvement and and QX. in towards mission by advance improve XX% from to that significant approximately cutting our in made in XX% infant by our rate these operating progress marketing basis, year-over-year, adjusted value on the loss a resulting year-over-year EBITDA focusing expenses goals per acquisition can and we including on significant reducing believe We shareholders. Owlet objectives, wellness to
revenue sell-through was sequential we in up strong see for channel to see cost demand aggressive these we consumer revenue continue to a as a XX% reductions, QX. Despite perspective, year-over-year typically From QX products. from decline our
QX year-over-year in you reflects large the comparisons first As that for so late QX, Dream impact. last had from our selling Sock initial year, we recall load-ins
managed addition, QX to improving reducing sell-in specifically for In in channel XXXX, stock support we certain levels. channel health goal areas in and our of our
We work improvements. are have do here, but to more we making
strong clearances continue create position more implementing health Overall, cost healthy marketing and consumer towards reductions accelerate channel stronger, continuous efficiencies, in achieving to in and work a a be and growth. we long-term as business will improving eventually achieving favorable while demand sustainable to
Sock. was XX, customer monitored Dream our Dream a launch, Sock QX in the launch, achieved anniversary new appropriate look significant over I of Sock to at progress NPS the heartbeats, made minutes over over thought with XX levels satisfaction. take Dream Sock our past Dream trillion X.X year. As a has high Owlet and of it we've demonstrating sold back Since XXX,XXX
products. our to in a parents showing demonstrating health for one row, market. the brand of the added the considered their Owlet monitoring in last registry wellness the strong also strength for Owlet Additionally, brand year, over in demand and in quarters category remains reputation our multiple XXX,XXX number and the
and here We customer further to-date, our on for feel. Baby have number one monitors ranked Smart Amazon highlighting leadership market
products, from to used life who parents our We've families. of our reinforcing the improve have hundreds also changing stories received of mission lives
into improves the We are health future. infant to safety driving committed and technology that
novo our towards and regulatory QX, approval XXX(k) In to results. focus making de QX product health, channel our on to operating we expenses, and continued rebuilding reestablishing baseline for applications. Turning our progress
partners. on normalizing was in due and our retail QX million QX to intentional inventory $XX both from seasonality $XX.X million, for focus Revenue with down sequentially channel
faced we followed sales shortly BABY, with QX addition, its bankruptcy announced January, a in announcement in growth thereafter. and retailer, large financial after headwinds trouble buybuy In
our take sell-in for channels. headwind specialty this the other aggressively XXXX, Target will will largest channels anticipate transition the Amazon the of be in As time we working demand. We space, Owlet retailer revenue ensure from it this balance for such with as BABY buybuy lost a for are demand and of but to recapture other to Babylist, to
since Sock report indicating introducing QX We sell-through QX last demand in continued to year. our XXXX, are the pleased compared our QX, that for strong XX% Dream was consumer up to products
Additionally, driving on we're through activities. continuing awareness raising and focus to consideration our organic
of with views our over organic content XX In million media. success QX, social saw through video we great
drive We continue expect to this QX. and trend further in growth
anticipated we begin and increase healthier between as to challenges health channel QX, expect QX and we see some unanticipated sequentially to sell-through. in a in balance revenue begin to Following our sell-in and normalize revenue
gross catalysts Specifically in events July. upcoming Prime margin XX.X%. expecting as Day such like Amazon QX, revenue we growth drive QX, Day in are seasonal to was sell-in and In Mother's
margin our and increase hard of gross to it's a and efficiency. continue significant operations dedication team optimize was in the to on Owlet testament and we This sequential as focus work the a
there's to as of work off year. RTV come, stabilizing we efforts we our While towards see the last business the activities more are pleased to following paying
to lowering with shipping XX% forward, warehousing to optimizations and through margins driving returning range, goal our Moving the returns we and inventory improve PPV time discounts. committed of in the remain improvement reduction we XX% our levels to and as our over reduce and in margin gross
committed organization. to expenses, create and a loss million. EBITDA more operating by to from adjusted leaner efficient successfully Our sequentially We adjusted our QX areas $X.X for down more continuing to We than identify efficiency half EBITDA brought loss cutting of our was QX. remain
our an loan in round payback our amended financing and SVB increase QX, closed the March lending eligibility and we to in $XX million in borrowing shared we call, period with our extension we principal to our As agreement asset-based of to base. an include
adjusted forward, late XXXX. support this our FDA EBITDA business position towards the a us cash Combined, the puts get in in ultimately moving will to clearances breakeven enable Owlet and business turning that continue
I'd the like on of received Stock from letter the briefly York noncompliance we New touch Exchange. to
role, We market cure available well continue minimum the options cap $X as as price threshold. the to minimum evaluate to both
to We have cure XX requirement. market the listing capitalization months
be sure to have you updated share. will material to when needs We keep we
to our our submission XXXX, prescription home FDA the We've for through new monitoring made platforms FDA progress who work. that a passport babies device clearances to BabySat be significant regulatory need two towards monitoring. will our in pursuing The for distinct including for Turning available for submissions. is medical
about notification, additional at health health real status baby's receive as the for will enable home. is de to Sock that their notifications medical product to device submission software While Dream a our parents existing novo an time
in and process questions to working promptly FDA review the currently come the or respond that with are We clarifications up. are any to
body a to Additionally, we our filing be in regulatory QX. in European Europe will submission notified
better pleased Owlet. and are long-term to We set Allowing and our tool and us the progress growth the our very critical as parents these clearances home gap here believe and care. a for use opportunities that with data the hospital between growing for achieving navigate unlock further will help large regulatory and pediatric
the include Promoter clearance time fronts. all at with at conclusion, profitability time In remains quarter made brand Score in achievements our highs. Net we and significant FDA towards highs all our health These on our multiple of for goals products progress
stabilized per spend of and and We've reduced cost XX% early acquisition levels. by marketing XXXX
normalizing last and healthier the over QX inventory channel is Our the channel has year, in levels. grown sell-through
track for us business $XX decreased Our on expenses corporate compensation excluding no more spending the has spend putting across year. full on adjusted million than operating to stock-based the
these see a path are products the move organization, believe and agreements forward. pursuing the We've of FDA forward growth towards have the towards that building we're and regulatory and position accelerate gap constant home. profitability. and two clearances. the We And clearances the to critical with we've secured foundation we platform strong path loan profitable have bridges for a creating sustainable submission, us communication been as adoption between confident a We're hospital we capital, our in about will and that FDA and progress that the clear our excited are the be we finally, we efficient on made an renegotiated we
We to journey, while through services confident shareholders. make operational and we our your strategy that look updating parent's products hands lives. our and hold our customers meaningful our focused to executing coming we a As continued forward you their to deliver value quarters. remain Kate, achieving are will and impact long-term on this and over time Thank support. on continuing you. the in you for We to goals, progress on our